# AcesoStem Biostrategies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acesostem-biostrategies

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Total disclosed funding: $4.3M
- Latest round: Series A (Jun 1, 2026)
- Investors on record: 5

## About

Based in Seoul, South Korea, and founded in 2019 by Professor Hyuncheol Cho, AcesoStem Biostrategies operates as a research and development company that develops therapies for intractable musculoskeletal disorders. In June 2026, AcesoStem Biostrategies raised KRW 4 billion in series A funding from new investor Premier Partners.

AcesoStem Biostrategies developing therapy based on smump cell is an umbilical cord-derived cell without aging and low immunogenicity and high immunomodulatory ability even in a pro-inflammatory lesion environment. It also develops cell tuning technology, including conditioning technology for cells and lesions.

The company will use the June 2026 funding to accelerate the phase 1/2a clinical trial of its rotator cuff, enter non-clinical and clinical trials for osteoarthritis treatments, and establish a new research and development center.

## Funding rounds

- Series A, Jun 1, 2026, $2.7M — Premier Partners
- Series A, Feb 7, 2022, $1.7M — Seoul Technology Holdings, BlissVine Ventures, Tap Angel Partners, Mira Ventures

## Investors

- Seoul Technology Holdings (https://capitalatlas.ai/funds/seoul-technology-holdings) — Series A
- BlissVine Ventures — Series A
- Tap Angel Partners (https://capitalatlas.ai/funds/tap-angel-partners) — Series A
- Mira Ventures — Series A
- Premier Partners (https://capitalatlas.ai/funds/premier-partners) — Series A